TetraLogic Pharmaceuticals (TetraLogic Pharmaceuticals) Market Cap : $0.00 Mil (As of May. 14, 2024)

View and export this data going back to 2013. Start your Free Trial

What is TetraLogic Pharmaceuticals Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). TetraLogic Pharmaceuticals's share price for the quarter that ended in Sep. 2016 was $0.16. TetraLogic Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Sep. 2016 was 24.77 Mil. Therefore, TetraLogic Pharmaceuticals's market cap for the quarter that ended in Sep. 2016 was $3.96 Mil.

TetraLogic Pharmaceuticals's quarterly market cap increased from Mar. 2016 ($4.46 Mil) to Jun. 2016 ($7.68 Mil) but then declined from Jun. 2016 ($7.68 Mil) to Sep. 2016 ($3.96 Mil).

TetraLogic Pharmaceuticals's annual market cap declined from Dec. 2013 ($211.34 Mil) to Dec. 2014 ($107.65 Mil) and declined from Dec. 2014 ($107.65 Mil) to Dec. 2015 ($42.85 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. TetraLogic Pharmaceuticals's Enterprise Value for Today is $0.00 Mil.

TetraLogic Pharmaceuticals Market Cap Historical Data

The historical data trend for TetraLogic Pharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TetraLogic Pharmaceuticals Market Cap Chart

TetraLogic Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Market Cap

211.34

107.65

42.85

TetraLogic Pharmaceuticals Quarterly Data
	Dec11	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
Market Cap	Get a 7-Day Free Trial														45.82	42.85	4.46	7.68	3.96

Competitive Comparison of TetraLogic Pharmaceuticals's Market Cap

For the Biotechnology subindustry, TetraLogic Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TetraLogic Pharmaceuticals's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TetraLogic Pharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where TetraLogic Pharmaceuticals's Market Cap falls into.

TetraLogic Pharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

TetraLogic Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2015 is calculated as

Market Cap (A: Dec. 2015 )	=	Share Price (A: Dec. 2015 )	*	Shares Outstanding (EOP) (A: Dec. 2015 )
	=	$1.73	*	24.7691
	=	$42.85

TetraLogic Pharmaceuticals's Market Cap for the quarter that ended in Sep. 2016 is calculated as

Market Cap (Q: Sep. 2016 )	=	Share Price (Q: Sep. 2016 )	*	Shares Outstanding (EOP) (Q: Sep. 2016 )
	=	$0.16	*	24.7691
	=	$3.96

TetraLogic Pharmaceuticals (OTCPK:TLOG) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

TetraLogic Pharmaceuticals Market Cap Related Terms

Thank you for viewing the detailed overview of TetraLogic Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

TetraLogic Pharmaceuticals (TetraLogic Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TetraLogic Pharmaceuticals Corp (OTCPK:TLOG) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

N/A

Address

343 Phoenixville Pike, Malvern, PA, USA, 19355

Website

http://www.tetralogicpharma.com

TetraLogic Pharmaceuticals Corp is a biopharmaceutical company. The company is engaged in developing novel small molecule therapeutics in oncology.

Executives

Hudson Bay Capital Management Lp	other: See Remarks	28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Lazard Asset Management Llc	other: See Remarks	30 ROCKEFELLER PLZ, 56TH FL., NEW YORK NY 10112
Nomura Holdings Inc	other: See Remarks	1-13-1 NIHONBASHI, CHUO-KU, TOKYO M0 103-8645
Whitebox Multi-strategy Partners Lp	other: See Remarks	3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416
Pandora Select Partners, L.p.	other: See Remarks	3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416
Whitebox General Partner Llc	other: See Remarks	3033 EXCELSIOR BLVD., SUITE 300, MINNEAPOLIS MN 55416
Highbridge Capital Management Llc	other: See Remarks	277 PARK AVE, 23RD FLOOR, NEW YORK NY 10172
Sander Gerber	other: See Remarks	C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Whitebox Concentrated Convertible Arbitrage Partners, L.p.	other: See Remarks	3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416
Whitebox Advisors Llc	other: See Remarks	3033 EXCELSIOR BLVD., SUITE 500, MINNEAPOLIS MN 55416
Patrick Hutchison	officer: CFO & Treasurer	C/O BIOSPECIFICS TECHNOLOGIES CORP 2 RIGHTER PARKWAY SUITE 200 WILMINGTON DE 19803
Clarus Ventures Ii, Llc	10 percent owner	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Clarus Lifesciences Ii, L.p.	10 percent owner	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Clarus Ventures Ii Gp, L.p.	10 percent owner	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Nicholas Simon	10 percent owner	101 MAIN STREET SUITE 1210, CAMBRIDGE MA 02142

TetraLogic Pharmaceuticals (TetraLogic Pharmaceuticals) Headlines

No Headlines